Skip to navigation Skip to content

Clinical Trial: Suvorexant for Fatigue and Insomnia

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To reduce fatigue and insomnia
Number of Subjects: 30
Medication: suvorexant
Location: Washington
Institutions: MS Center at EvergreenHealth
12039 NE 128th Street, Suite 300
Kirkland, WA 98034 Contact Information
Gowri Rajendran
425-899-5370
GRajendran@evergreenhealth.com

Funding:

Merck Sharp & Dohme Corp.

Description

The MS Center at EvergreenHealth is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue. This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45 – 90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.